Down-Regulation of Placental Transport of Amino Acids Precedes the Development of Intrauterine Growth Restriction in Maternal Nutrient Restricted Baboons

Priyadarshini Pantham, Fredrick J. Rosario, Susan T. Weintraub, Peter W. Nathanielsz, Theresa L. Powell, Cun Li, and Thomas Jansson

Abstract

Intrauterine growth restriction (IUGR) is an important risk factor for perinatal complications and adult disease. IUGR is associated with down-regulation of placental amino acid transporter expression and activity at birth. It is unknown whether these changes are a cause or a consequence of human IUGR. We hypothesized that placental amino acid transport capacity is reduced prior to onset of reduced fetal growth in baboons with maternal nutrient restriction (MNR). Pregnant baboons were fed either a control (n = 8) or MNR diet (70% of control diet, n = 9) from Gestational Day 30. At Gestational Day 120 (0.65 of gestation), fetuses and placentas were collected. Microvillous (MVM) and basal (BM) plasma membrane vesicles were isolated. System A and system L transport activity was determined in MVM, and leucine transporter activity was assessed in BM using radiolabeled substrates. MVM amino acid transporter isoform expression (SNAT1, SNAT2, and SNAT4 and LAT1 and LAT2) was measured using Western blots. LAT1 and LAT2 expression were also determined in BM. Maternal and fetal plasma amino acids concentrations were determined using mass spectrometry. Fetal and placental weights were unaffected by MNR. MVM system A activity was decreased by 37% in MNR baboon placentas (P = 0.03); however MVM system A amino acid transporter protein expression was unchanged. MVM system L activity and BM leucine transporter activity were not altered by MNR. Fetal plasma concentrations of essential amino acids isoleucine and leucine were reduced, while citrulline increased (P < 0.05) in MNR fetuses compared to controls. In this primate model of IUGR, placental MVM system A amino acid transporter activity is decreased prior to the onset of reduction in the fetal growth trajectory. The reduction in plasma leucine and isoleucine in MNR fetuses may be caused by reduced activity of MVM system A, which is strongly coupled with system L essential amino acid uptake. Our findings indicate that reduced placental amino acid transport may be a cause rather than a consequence of IUGR due to inadequate maternal nutrition.

Intraterine growth restriction (IUGR), nutrition, placenta, placental transport, pregnancy

Introduction

Maternal undernutrition is the most common cause of intrauterine growth restriction (IUGR) in developing countries. In the United States, more than 50 million households have been reported to experience food insecurity or hunger at least sometime during the year [1], indicating that maternal undernutrition remains a significant problem also in developed countries. IUGR is in turn associated with increased perinatal mortality and morbidity [2] as well as increased risk of offspring developing cardiovascular and metabolic disease in childhood and later life [3]. The mechanisms linking maternal undernutrition, IUGR, and developmental programming are poorly understood. IUGR in humans and animal models is associated with specific alterations in the activity and expression of placental nutrient transporters, which have been suggested to contribute to the development of IUGR [4–7]. Because of the lack of noninvasive approaches to assess placental function in women, studies of placental transport prior to term rely on collecting the placenta after delivery and therefore often suffer from being influenced by the effect of preterm birth. The time course of changes in nutrient transport capacity relative to changes in fetal growth during pregnancy therefore remains largely unknown.

The syncytiotrophoblast is the transporting epithelium of the human placenta and is believed to be the primary barrier for transfer of most nutrients from the maternal to the fetal circulation. Specifically, transport across the polarized plasma membranes of the syncytiotrophoblast, the microvillous (MVM) and basal (BM) membranes constitutes the rate-limiting step in transplacental amino acid transfer [8]. The MVM and BM have distinct transport properties, including large differences in surface area (MVM surface area is six times larger than those of the BM) [9] and unequal distribution of placental amino acid transporters [10]. Transplacental amino acid transport is active (energy requiring), resulting in higher amino acid concentrations in the fetal than in maternal blood. The active step in maternal-to-fetal transfer of amino acids is

Support: NIH grant P01HD21350. Mass spectrometry analyses were conducted in the metabolomics component of the UTHSCSA Mass Spectrometry Laboratory, supported by UTHSCSA and by an award from the National Institutes of Health, 1S10RR031586-01 (S.T.W.).

Correspondence and current address: Priyadarshini Pantham, Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, 1206 W Gregory Dr., Urbana, IL 61801.
E-mail: pantham@illinois.edu

Received: 13 April 2016.
First decision: 31 May 2016.
Accepted: 24 August 2016.
© 2016 by the Society for the Study of Reproduction, Inc. This article is available under a Creative Commons License 4.0 (Attribution-Non-Commercial), as described at http://creativecommons.org/licenses/by-nc/4.0/
eISSN: 1529-7268 http://www.biolreprod.org
ISSN: 0006-3363
localized in the MVM, in most cases energized by the inwardly directed Na\(^+\) gradient, resulting in high intracellular amino acid concentrations in the syncytiotrophoblast. In contrast, transport across the BM occurs via facilitated diffusion down a diffusion gradient mediated by specific transporter systems [8]. Because MVM amino acid uptake is not only dependent on the expression and activity of specific amino acid transporter isoforms, which is subjected to complex regulation, but also modulated by the energy status of the cell, the transport of amino acids across MVM is believed to be the primary rate-limiting step for transplacental amino acid transfer [8].

One of the key amino acid transporters is system A, a Na\(^+\)-dependent transport system, which mediates the uptake of neutral amino acids. The system A amino acid transporter is encoded by three members of the \(\text{slc38}\) family, and all three isoforms (Na\(^+\)-coupled neutral amino acid transporters SNAT1, 2, and 4) are expressed in the human placenta [11, 12]. The maximal transport capacity of system A is much higher in the MVM than the BM [13]. System A establishes a high intracellular concentration of nonessential amino acids such as glycine, glutamine, and serine, creating a gradient that drives the exchange for essential amino acids via system L [14]. System A activity is therefore necessary for the uptake of both essential and nonessential amino acids. System L, an amino acid exchanger, mediates the uptake of essential amino acids in a Na\(^+\)-independent manner. System L is a heterodimer made up of a light chain, (large amino acid transporter LAT1 or 2), and a heavy chain (4F2hc/CD98) [14]. In the BM, the system L [4, 15, 16] and efflux transporters such as LAT3 [17] are responsible for the transfer of essential amino acids to the fetus.

MVM system A activity is decreased in human IUGR [18] and may be related to the degree of severity of growth restriction [19]. Leucine transport is reduced in both MVM and BM isolated from human term placentas of IUGR pregnancies [4]. Reduced fetal plasma concentrations of several amino acids are also observed in IUGR at term [20]. However, it is not yet established if these changes in amino acid transporter activity occur as a primary event, directly contributing to the pathophysiology of IUGR, or as a secondary consequence of reduced fetal growth and decreased demand. Determining whether changes in placental amino acid transporter expression and activity precede the development of IUGR would provide interesting possible targets for manipulation of these transporters as treatment in order to prevent IUGR. To this end, we have demonstrated that down-regulation of system A activity and expression precedes the development of IUGR in a rat model following a low protein diet [6]. However, rodent placentation is distinct from the human. Studies using nonhuman primate models are more informative and are directly comparable to the human in terms of maternal physiological changes of pregnancy and placentation. Using a baboon model of maternal nutrient restriction (MNR), we have recently shown that protein expression of amino acid transporters SNAT2, LAT1 and 2, and taurine transporter TAUT is reduced in MVM of placentas from MNR baboons near term at Gestational Day (GD) 165, which equates to 0.9 of gestation, compared with controls [7]. These changes are concurrent with reductions in system A and system L transporter activity in MVM in placentas of MNR baboons [21]. At GD 165, IUGR has developed in response to MNR. In the study reported here, we used in vitro approaches to test the hypothesis that placental amino acid transport capacity is reduced prior to the onset of reduced fetal growth in baboons with MNR.
PLACENTAL AMINO ACID TRANSPORT REDUCES BEFORE IUGR

In leucine transport experiments, nonmediated flux was studied in the presence of 20 mmol/L unlabeled L-leucine. Each condition was measured in triplicate for each placenta in all uptake experiments.

Filters were dissolved in 2 ml scintillation cocktail and counted. Blanks were subtracted from counts, and uptakes are expressed as picomoles per milligram protein and time. System A activity corresponding to the Na+-dependent uptake of MeAIB was calculated by subtracting Na+-independent uptake from total uptakes. Mediated uptake of leucine was calculated by subtracting nonmediated transport from total uptake. Protein content was measured using the Bradford assay [27].

Amino Acid Analysis

A 20 μl plasma aliquot was combined with stable isotope-labeled internal standards and sodium tetraborate solution prior to derivatization with 5-(dimethylamino) naphthalene-1-sulfonyl chloride. After evaporation to dryness by vacuum centrifugation, the derivatized amino acids were dissolved in mobile phase A (see below) and transferred to autosampler vials for high-performance liquid chromatography (HPLC)-electrospray ionization-mass spectrometry analysis on a Thermo Fisher X Q Exactive mass spectrometer used in conjunction with a Thermo Fisher/Dionex Ultimate 3000 HPLC. Analytical conditions were: HPLC column, Ketrex C18 (2.1 × 100 mm, 2.6 μm, 100 A; Phenomenex); mobile phase A, acetonitrile:water/formic acid (5:95:0.5); mobile phase B, acetonitrile:water/formic acid (95:5:0.5); flow rate, 400 μl/min; gradient, 10% B to 90% B over 5 min then held at 90% B for 3 min. Mass spectrometer parameters were: electrospray ionization; scan range, m/z 300–1000; resolution, 70000 (m/z 300); positive ion detection. Extracted ion chromatograms were generated for the protonated molecule for each derivatized amino acid using a mass window of ± 5 parts per million. Peak areas were determined by processing through QuanBrowser (Thermo Fisher) and compared to calibration curves that were generated by analysis of authentic standards. Linear least squares analysis of the standard 101 curves yielded R² values of ≥0.99.

Statistical Analysis

The data were found to be normally distributed using the Kolmogorov-Smirnov test; hence a parametric test was applied, and data are represented as mean ± SEM. Amino acid data were transformed to natural logs prior to testing. The significance of the difference between the two groups was calculated using the unpaired Student t-test. Spearman correlation coefficients were calculated for each amino acid to analyze the correlation between maternal and fetal amino acid concentrations in the control and MNR groups. A P-value of less than 0.05 was considered significant.

RESULTS

Fetal and Placental Weights

Fetal and placental weights were not different between the control and MNR groups at GD 120 (n = 8 control, n = 9 MNR, P = 0.73; Table 1). Fetal and placental weights were positively correlated in the MNR group but not in the controls (control, n = 8, r = 0.28, P = 0.5 vs. MNR, n = 9, r = 0.75, P = 0.02; Fig. 1).

Maternal and fetal plasma amino acid concentrations.

Maternal and fetal plasma amino acid concentrations are presented in Table 2. Amino acid concentrations were similar in control and MNR mothers (Table 2). Fetal plasma concentrations of leucine and isoleucine (P < 0.05) were decreased in MNR while fetal citrulline was increased (P < 0.05; Table 3). The maternal and fetal concentrations of alanine were found to be significantly correlated in both the control (r = 0.976, P = 0.004) and MNR (r = 0.733, P = 0.03) groups, albeit without a significant difference in absolute concentrations of alanine between the control and MNR groups in the mother and fetus (P < 0.05). Maternal and fetal concentrations of arginine, citrulline, isoleucine, lysine, threonine, and valine were positively correlated with each other in the control group alone; while maternal and fetal concentrations of cysteine, glutamine, glycine, histidine, phenylalanine, and proline were positively correlated with each other only in the MNR group (Table 4).

Activity of Amino Acid Transporters in MVM and BM

System A transporter activity was assessed in MVM by measuring the uptake of the amino acid analog methylaminoisobutyric acid (MeAIB) using a modification of the protocol of Mahendran et al. [18]. System L activity (MVM) and leucine uptake (BM) was studied by determining the transport of L-leucine as described previously [4, 13] with minor modifications. The quantitative contribution of BM system A to the flux of neutral amino acids across the placental barrier is therefore minimal, in particular when considering the much smaller surface area of the BM [13]. Using 2-aminobicyclo[2.2.1]-heptane-2-carboxylic acid (BCH), a specific system L inhibitor, we have previously reported that leucine uptake in human MVM is mediated almost exclusively by system L [4], providing the justification for using unlabeled leucine to determine system L activity in MVM.

In the BM, leucine transport is mediated by efflux transporters such as LAT3 [17], in addition to system L. This provides the rationale to designate BM leucine transport inhabitable by unlabeled leucine as mediated leucine transport rather than system L transport.

Vesicles were preloaded and incubated overnight in 300 mmol/L mannitol and 10 mmol/L HEPES-Tris, pH 7.4, at 4°C. Vesicles were subsequently pelleted and resuspended in the same buffer at a protein concentration of 150 μmol/L. After incubation, the uptake of [14C]-MeAIB (150 μmol/L) at 60°C, leucine (0.375 μmol/L/L). To determine the time course of MeAIB and leucine uptake by MVM (n = 3), uptake of radiolabeled leucine was terminated at 8, 12, 20, and 30 sec using ice-cold PBS (pH 7.4) followed by rapid filtration. The uptake of MeAIB was rapid and time dependent, not reaching equilibrium by 20 sec (data not shown). Uptakes at 15 sec were chosen to approximate initial rate in final experiments (n = 8 control, n = 9 MNR). To determine the time course of leucine uptake in BM (n = 3), uptake of radiolabeled leucine was terminated at 8, 12, 20, and 30 sec using ice-cold PBS (pH 7.4) followed by rapid filtration. The uptake of leucine in BM was rapid and time dependent, not reaching equilibrium by 10 sec (data not shown). Uptake at 8 sec was chosen to approximate initial rate in final experiments (n = 8 control, n = 9 MNR).

After defined incubation times, vesicles were separated from the substrate medium using rapid filtration over mixed ester filters (0.45 μm pore size; Millipore Corporation) and washed using three times with 2 ml PBS. In studies of MeAIB transport, 150 mmol/L NaCl and 150 mmol/L KCl were used in incubation buffers to measure total and Na+-independent uptake, respectively.

### Table 1. Fetal and placental weights in control and MNR baboons at GD 120.

| Parameter | Control | MNR |
|-----------|---------|-----|
| Number of baboons | 6 (6 males, 2 females) | 9 (7 males, 2 females) |
| Fetal weight (g) | 328 ± 22.4 | 321 ± 12.2 |
| Placental weight (g) | 139 ± 9.5 | 135 ± 6.9 |

*G.D., gestational day; MNR, maternal nutrient restriction.*

A affinity-purified polyclonal anti-SNAT4 antibodies were produced in rabbits using the epitope YGEVEDELLHAYSKV in human SNAT4 (Eurorgenec). Antibodies targeting LAT1 and LAT2 were produced in rabbits as described previously [29]. GLUT1 and TAUT antibodies were purchased from Millipore.

Western blot analysis was performed as described previously [7]. Briefly, 20 μg of protein was loaded onto a Bio-Rad Any KD TGX precast polyacrylamide gel, and electrophoresis was performed at 200 V for 40 min. Proteins were transferred onto polyvinylidene fluoride membranes at a constant 35 V. After transfer, membranes were blocked in 5% milk in Tris-buffered saline (w/v) plus 0.1% Tween 80 (v/v) for 1 h at room temperature. Membranes were incubated with primary antibodies overnight at 4°C. Membranes were subsequently incubated with the appropriate peroxidase-labeled secondary antibodies for 1 h at room temperature. After washing, bands were visualized using enhanced chemiluminescence detection reagents (Pierce Biotechnology). Blots were stripped using ReBlot Plus Mild antibody stripping solution (Millipore) and reprobed for β-actin as a loading control. Analysis of the blots was performed by densitometry using Image J software. For each protein target, the mean density of the control sample band was arbitrarily assigned a value of 1. Subsequently, all individual MNR density values were expressed relative to this mean.
controls (control, n of system L activity, was unchanged in MNR compared to 5B) at GD 120.

Glucose and amino acid transporter expression in MVM.
Protein expression of glucose transporter GLUT1 and amino acid transporters TAUT (Fig. 2), SNAT1, 2, and 4 (Fig. 3), and LAT1 and 2 (Fig. 4) were unchanged in MVM isolated from placentas of baboons fed a MNR diet compared to controls (n = 8 control, n = 9 MNR, P > 0.05).

System A and System L Activity in MVM
At GD 120, MVM uptake of MeAIB was reduced by 37% in MNR compared to controls (control, n = 8, 26.7 ± 3.2 pmol/mg ×15 sec vs. MNR, n = 9, 16.7 ± 2.4 pmol/mg ×15 sec, *P = 0.035; Fig. 5A). Mediated MVM L-leucine uptake, indicative of system L activity, was unchanged in MNR compared to controls (control, n = 8, 0.18 ± 0.03 pmol/mg ×15 sec vs. MNR, n = 9, 0.12 ± 0.01 pmol/mg ×15 sec, P = 0.35; Fig. 5B) at GD 120.

TABLE 3. Fetal plasma amino acid concentrations in control and MNR baboons at GD 120.

| Amino acid   | Control b | MNR b | P-value |
|--------------|-----------|-------|---------|
| Alanine      | 321.4 ± 40.4 | 306 ± 24.5 | 0.89    |
| Arginine     | 119.1 ± 14.4 | 139.3 ± 9.7 | 0.2     |
| Asparagine   | 54.2 ± 4.3 | 45.8 ± 2.3 | 0.09    |
| Aspartic acid| 3.2 ± 0.2 | 4.3 ± 0.6 | 0.17    |
| Citrulline   | 25.2 ± 4 | 33.1 ± 1.1 | 0.02*   |
| Cysteine     | 31.1 ± 2.1 | 31.5 ± 1.7 | 0.86    |
| Glutamine    | 472.1 ± 21.8 | 478.3 ± 29.1 | 0.94    |
| Glycine      | 315.6 ± 13.6 | 319 ± 15.9 | 0.91    |
| Glutamic acid| 29.9 ± 4.7 | 29 ± 3.3 | 0.94    |
| Histidine    | 272.4 ± 49.7 | 382.8 ± 41.7 | 0.12    |
| Isoleucine   | 92.9 ± 8.3 | 70.9 ± 3.1 | 0.0180* |
| Leucine      | 119.3 ± 9.1 | 92.6 ± 6.3 | 0.0454* |
| Lysine       | 510.1 ± 45.2 | 508 ± 22 | 0.85    |
| Methionine   | 67 ± 4.8 | 59.8 ± 3.1 | 0.72    |
| Ornithine    | 70.7 ± 10.7 | 68.5 ± 5.2 | 0.96    |
| Phenylalanine| 68.1 ± 4.4 | 63.5 ± 4.6 | 0.45    |
| Proline      | 167.8 ± 14.2 | 190.3 ± 13.5 | 0.25    |
| Hydroxyproline| 84.4 ± 4 | 85.5 ± 4.7 | 0.92    |
| Serine       | 159.6 ± 13.6 | 174.8 ± 13.7 | 0.43    |
| Threonine    | 170 ± 21.5 | 172.4 ± 12.7 | 0.74    |
| Tryptophan   | 65.3 ± 6 | 62.5 ± 5.4 | 0.76    |
| Valine       | 246.7 ± 24.3 | 195.2 ± 8.7 | 0.07    |

a GD, gestational day; MNR, maternal nutrient restriction.
b Amino acid concentrations (μM). Values are given as mean ± SEM, n = 8 control and n = 9 MNR.

TABLE 4. Correlation between maternal and fetal amino acid concentrations in control and MNR baboons at GD 120.

| Amino acid b | Control (Spearman r, P-value) | MNR (Spearman r, P-value) |
|--------------|-------------------------------|---------------------------|
| Alanine      | (0.98,0.0004)*               | (0.73,0.03)*              |
| Arginine     | (0.92,0.002)*                | (0.25,0.51)               |
| Asparagine   | (0.67,0.08)                  | (0.45,0.23)               |
| Aspartic acid| (0.66,0.08)                  | (0.27,0.49)               |
| Citrulline   | (0.75,0.05)*                 | (0.67,0.06)               |
| Cysteine     | (0.71,0.06)                  | (0.79,0.01)*              |
| Glutamine    | (0.55,0.17)                  | (0.8,0.01)*               |
| Glycine      | (−0.39,0.33)                 | (0.95,0.0004)*            |
| Glutamic acid| (0.46,0.46)                  | (0.49,0.49)               |
| Histidine    | (0.55,0.17)                  | (0.93,0.0007)*            |
| Isoleucine   | (0.85,0.01)*                 | (0.3,0.43)                |
| Leucine      | (0.57,0.15)                  | (0.6,0.09)                |
| Lysine       | (0.83,0.01)*                 | (0.3,0.43)                |
| Methionine   | (0.16,0.7)                   | (0.08,0.04)               |
| Ornithine    | (0.64,0.09)                  | (0.11,0.77)               |
| Phenylalanine| (0.26,0.53)                  | (0.84,0.005)*             |
| Proline      | (0.45,0.26)                  | (0.71,0.03)*              |
| Hydroxyproline| (−0.26,0.33)                | (0.4,0.27)                |
| Serine       | (0.4,0.32)                   | (0.57,0.12)               |
| Threonine    | (0.92,0.002)*                | (0.41,0.27)               |
| Tryptophan   | (0.26,0.53)                  | (0.6,0.09)                |
| Valine       | (0.73,0.04)*                 | (0.48,0.19)               |

a GD, gestational day; MNR, maternal nutrient restriction.
b Amino acid concentrations (μM).
P < 0.05.
Importantly, of the two essential amino acids that were amino acid in both the control and the MNR groups. human pregnancy. of food insecurity or hunger at least sometime during the year in than 50 million households have been reported to experience the most common cause of IUGR globally and given that more third of the myometrium [30]. Maternal undernutrition remains invasion of the maternal spiral arteries occurs up to the inner hemochorial placenta with a villous structure and trophoblast [6]. However, rodent and human placentas differ significantly transport may be a cause rather than a consequence of IUGR. These findings have important implications for our understanding of the pathophysiology of restricted fetal growth and can inform efforts to develop effective intervention strategies in IUGR.

We have previously demonstrated that down-regulation of system A activity precedes the development of IUGR in rats fed a low-protein diet, suggesting that reduced amino acid transport may be a cause rather than a consequence of IUGR [6]. However, rodent and human placentas differ significantly with respect to structure and function. For example, trophoblast invasion is shallow in the rodent placenta and deep in the human [30]. Therefore, in terms of placentation, it is difficult to extrapolate findings in rodents to the human. In contrast, placentation in nonhuman primates, such as the baboon, is strikingly similar to the human, as they have a discoid, hemochorial placenta with a villous structure and trophoblast invasion of the maternal spiral arteries occurs up to the inner third of the myometrium [30]. Maternal undernutrition remains the most common cause of IUGR globally and given that more than 50 million households have been reported to experience food insecurity or hunger at least sometime during the year in the United States [1], our findings have broad applicability for human pregnancy. With alanine as the only exception, maternal and fetal plasma concentrations were not significantly correlated for any amino acid in both the control and the MNR groups. Importantly, of the two essential amino acids that were decreased in fetal circulation in MNR, leucine concentrations were not correlated between the maternal and fetal circulation in either the control or MNR group and isoleucine concentrations in maternal and fetal plasma were only significantly correlated in the control group. This may be a consequence of the active nature of placental amino acid transport and the complex metabolism of amino acids in the placenta and suggest that changes in fetal amino acid concentrations in MNR are unlikely to be caused by changes in maternal plasma concentration of amino acids alone. We have previously reported maternal and fetal amino acid plasma concentrations at midgestation (GD 90, 0.5 gestation) [32], and late third trimester (GD 165, 0.9 gestation) [7] in control and MNR animals. Thus, with the data presented in the current study (GD 120, 0.6 of gestation), corresponding to late second trimester, it is possible to compare significant changes in individual amino acids in maternal and fetal plasma across gestation in this baboon model of MNR (Table 5). At GD 90, there were no differences in maternal and fetal plasma amino acid concentrations between control and MNR animals [32]. At GD 120, prior to reduction in fetal and placental weight in baboons with MNR, we found significantly reduced fetal plasma amino acid concentrations in control (C) and MNR (M) baboons at GD 120. Histogram summarizing Western blot analysis data. Equal loading was performed. After normalization to β-actin, the mean density of C samples was assigned an arbitrary value of 1. Values given as mean ± SEM. *P < 0.05, unpaired Student t-test (n = 8 control; n = 9 MNR).

DISCUSSION
The human placenta is largely inaccessible prior to delivery, and there are currently no approaches to measure placental functions, such as nutrient transport, across gestation in women. As a result, there is no information on placentental nutrient transport prior to the development of human IUGR. MNR in the baboon is a well-established model of IUGR with extensive similarities to human IUGR [7, 21, 22, 30–32]. In this report, we used this model to demonstrate for the first time that MNR from GD 30 to GD 120 in the baboon is associated with 1) reduced activity of placental amino acid transport system A in isolated MVM and 2) decreased fetal plasma amino acid concentrations of leucine and isoleucine, and increased concentrations of citrulline, prior to the development of IUGR. Our data support the concept that down-regulation of placental nutrient transport is a primary event, which directly contributes to IUGR. Therefore, in terms of placentation, it is difficult to extrapolate findings in rodents to the human. In contrast, placentation in nonhuman primates, such as the baboon, is strikingly similar to the human, as they have a discoid, hemochorial placenta with a villous structure and trophoblast invasion of the maternal spiral arteries occurs up to the inner third of the myometrium [30]. Maternal undernutrition remains the most common cause of IUGR globally and given that more than 50 million households have been reported to experience food insecurity or hunger at least sometime during the year in the United States [1], our findings have broad applicability for human pregnancy.

With alanine as the only exception, maternal and fetal plasma concentrations were not significantly correlated for any amino acid in both the control and the MNR groups. Importantly, of the two essential amino acids that were
concentrations of leucine and isoleucine, independent of changes in maternal amino acid concentrations. At GD 165, maternal plasma concentrations of eight amino acids, including leucine and isoleucine, are decreased in MNR [7]. Reduced fetal plasma concentrations of the essential amino acids leucine, phenylalanine, and methionine at GD 165 coincided with down-regulation of placental amino acid transport activity as measured in MVM in vitro, decreased transplacental transport of essential amino acids in vivo, and IUGR at this gestational age [7, 21]. This highlights the importance of decreased fetal availability of essential amino acids, in particular leucine, in the development of IUGR. In support of this idea, decreased fetomaternal enrichment ratios of leucine have been reported to be correlated with the severity of IUGR in the human at term [33, 34]. Furthermore, leucine supplementation has been shown to prevent fetal growth restriction in rats fed a low protein diet [35].

Leucine transport has been reported to be reduced in MVM (−46%) and BM (−38%) isolated from IUGR term human placentas [4]. While most neutral amino acids are transported by the Na\(^{+}\)-dependent transporter system A across the MVM, leucine and isoleucine are primarily transported by system L [4]. Addition of BCH, a specific system L inhibitor, reduces the transport of leucine by MVM to near zero [4]. Conversely, leucine transport across the BM is not entirely suppressed by the addition of BCH, indicating that other mechanisms apart from system L exist to transport leucine across the BM into the fetal circulation, one of which may be substantial non-transporter-mediated transport due to increased membrane fluidity [36] and transporters such as LAT3 [17]. In the present study, we demonstrate that while fetal plasma amino acid concentrations of leucine and isoleucine are decreased, there is no decrease in system L activity in the MVM or leucine transport in the BM. This may be explained by the complex mechanisms of transplacental leucine transport.

The intracellular concentration of leucine in the syncytiotrophoblast is approximately six times higher than in maternal plasma [37]. While the exact mechanisms driving the uphill transport of leucine across the MVM remain to be established, previous work has shown that a high intracellular concentration of other neutral amino acids such as glycine, which is mainly transported across the MVM by system A, may be responsible for creating an uphill gradient driving leucine uptake into the MVM [4]. Glycine is found in high concentrations in the placenta but is limited in fetal circulation, suggesting that it may diffuse back into the maternal circulation [38]. Because glycine is also accepted by system L, an outwardly directed glycine gradient from the MVM back into the maternal circulation may drive the uptake of system L substrates such as leucine and isoleucine across the MVM [4]. In this study, we report decreased activity of system A but not system L in MVM isolated from baboons with MNR at GD 120. It is therefore possible that impaired uptake of nonessential neutral amino acids such as glycine via system A leads to a reduced gradient to drive uphill transport of leucine and isoleucine via system L in vivo, resulting in reduced concentrations of leucine and isoleucine in the fetal circulation.

While we have shown a reduction in the activity of system A transporters in the MVM in response to MNR at GD 120, no changes were observed in corresponding isofrom protein

![FIG. 5. A) Decreased MVM system A activity in MNR. Mediated MeAIB uptake into MVM vesicles isolated from control and MNR placentas of baboons at GD 120. Control and MNR groups were compared using the t-test (n = 8 control, n = 9 MNR, *P < 0.05). B) No change in MVM system L activity in MNR. Mediated L-leucine uptake into MVM vesicles isolated from control and MNR placentas of baboons at GD 120. Control and MNR groups were compared using the t-test (n = 8 control, n = 9 MNR, *P < 0.05).](image)

| Gestation day | Maternal (MNR vs. control) | Fetal (MNR vs. control) |
|--------------|---------------------------|-------------------------|
| GD 90 [32]   | ←                        | ←                       |
| GD 120       | ←                        | ←                       |
| GD 165 [7]   | [Arginine, glycine, lysine] | [Aspartic acid, citrulline, ornithine] |
|              | [Aspartic acid, glutamic acid, tyrosine, tryptophan, phenylalanine, isoleucine, leucine, ornithine] | [Aspartic acid, taurine, tyrosine, methionine, phenylalanine, leucine, ornithine] |

* MNR, maternal nutrient restriction.

Arrows indicate: no change in amino acid concentration (←); an increase in amino acid concentration (↑); and a decrease in amino acid concentration (↓).
Western blot analysis data. Equal loading was performed. After normalization to system L amino acid transporter isoforms LAT1 and LAT2 in BM isolated from control (C) and MNR (M) baboons at GD 120. Histogram summarizing citrulline transport appears to occur via Na$^+$ and the apical membrane of renal proximal tubular cells, of citrulline is not well characterized. In the rat small intestine by nitric oxide synthase activity [39]. Transplacental transport enzymatic by-product of nitric oxide synthesis from arginine [7]. Increased fetal circulating citrulline was also observed in baboons fed a MNR diet at GD 120. Citrulline is formed as an enzymatic by-product of nitric oxide synthesis from arginine by nitric oxide synthase activity [39]. Transplacental transport of citrulline is not well characterized. In the rat small intestine and the apical membrane of renal proximal tubular cells, citrulline transport appears to occur via Na$^+$-dependent systems [40, 41]. IUGR is associated with elevated levels of maternal arginine [42], but intracellular arginine and citrulline are reduced in human umbilical vein cells (HUVECs) [39]. In HUVECs, arginine and citrulline are transported via system y$^+$ / CATs (cationic amino acid transporters), and HUVEC y$^+$/CAT activity and expression is decreased in IUGR [39]. In response to MNR in the baboon at GD 165, maternal plasma arginine is elevated, while fetal plasma arginine and citrulline concentrations are increased (albeit these changes were not significant) compared to controls [7]. While increased fetal citrulline was significant, nonsignificant elevations in maternal plasma arginine and citrulline as well as fetal arginine were observed in response to MNR in the baboon at GD 120. It is therefore possible that increased production of citrulline from arginine is responsible for elevated fetal amino acid concentration of citrulline in MNR; however, further work is required to elucidate the mechanisms underlying this increase.

Predominantly based on elegant mouse studies, it has been proposed that placental function is primarily controlled by fetal demand [43–45]. For example, in response to maternal undernutrition or restricted utero-placental blood flow, resulting in decreased placent al transfer and limited fetal nutrient availability, the fetal demand model of placental function predicts that the fetus signals to its placenta to up-regulate placental growth and nutrient transport. This model represents a classical homeostatic mechanism by which the fetus compensates for decreased nutrient availability by regulating nutrient supply (i.e., placental transport) in the opposite direction, thereby correcting for deficiencies. However, with few exceptions [44], there are few known fetal demand signals in the human. For example, key placental transporters for amino acids and ions are in general down-regulated in human IUGR, which is inconsistent with a homeostatic or fetal demand model for regulation of placent al transport. However, most of these studies were performed at term, and it cannot be excluded that compensatory changes consistent with fetal demand signals are present earlier in pregnancy, as has been shown in mouse models of IUGR [43–45]. In the current study of a well-established IUGR model in baboon, a species with close relationship to the human, we found no evidence of compensatory up-regulation of nutrient transporters at GD 120, corresponding to late second trimester in the human. These observations suggest that the primates lack strong fetal demand signals that regulate placent al function.

In this study, we have utilized a nonhuman primate model with extensive similarities to human IUGR, and our studies are therefore relevant to the development of restricted fetal growth in women. Although strongly motivated by the high human relevance of the data obtained, nonhuman primate research is a continuous balancing act between, on one hand, the exhaustive costs for each individual experiment and the ethical requirement to minimize the number of animals used and, on the other hand, the risk for Type I/II errors. With eight and nine animals,
respectively, in the two groups, we strongly feel that we have found a reasonable balance between these two opposing aspects. However, the relatively small sample size is a potential limitation of the study.

In this study, we report that reduction in placental nutrient transporter activity occurs at 0.65 of gestation, prior to the development of IUGR, following moderate MNR in a well-established baboon model that has extensive similarities to the human IUGR. We have suggested that the placenta functions as a nutrient sensor, regulating fetal growth rate to match the ability of the maternal supply line to deliver nutrients by altering placental nutrient transport and nutrient delivery to the fetus [6, 46]. The reduction of system A transport in MVM in response to MNR remains to be elucidated. The exact mechanism by which system A transporter activity is reduced in MVM in response to MNR remains to be elucidated.

ACKNOWLEDGMENT

We are grateful for the expert contributions of Xiaoli Gao, Ph.D.

REFERENCES

1. Nord M, Coleman-Jensen A, Andrews M, Carlson S. Household food security in the United States, 2009. United States Department of Agriculture, Economic Research Services 2010.

2. Brodsky D, Christou H. Current concepts in intrauterine growth restriction. J Intensive Care Med 2004; 19:307–319.

3. Barker DJ, Gluckman PD, Godfrey KM, Harding JE, Owens JA, Robinson JS. Fetal nutrition and cardiovascular disease in adult life. Lancet 1993; 341:938–941.

4. Jansson T, Scholthach V, Powell TL. Placental transport of leucine and lysine is reduced in intrauterine growth restriction. Pediatr Res 1998; 44:532–537.

5. Norberg S, Powell TL, Jansson T. Intrauterine growth restriction is associated with a reduced activity of placental taurine transporters. Pediatr Res 1998; 44:223–238.

6. Jansson N, Pettersson J, Haafiz A, Ericsson A, Palmberg I, Tranberg M, Pettersson J, Haafiz A, Ericsson A, Palmberg I, Tranberg M, Jansson T. Down-regulation of placental transport of amino acids precedes the development of intrauterine growth restriction in rats fed a low protein diet. J Physiol 2006; 576:935–946.

7. Kaviitha J, Rosario FJ, Nijland MJ, McDonald TJ, Wu G, Kanai Y, Powell TL, Nathanielsz PW, Jansson T. Down-regulation of placental mTOR, insulin/IGF-I signaling, and nutrient transporters in response to maternal nutrient restriction in the baboon. Am J Physiol-Regul Integr Comp Physiol 2000; 279:R287–R294.

8. Jansson T, Amino acid transporters in the human placenta. Pediatr Res 2001; 49:141–147.

9. Teasdale F, Jeanjacques G. Intrauterine growth retardation–morphometry of the microvillous membrane of the human-placenta. Placenta 1988; 9:47–55.

10. Moe AJ. Placental amino-acid-transport. Am J Physiol 1995; 268:C1321–C1331.

11. Desforges M, Lacey HA, Glazier JD, Greenwood SL, Lynett KJ, Speake PF, Sibley CP. SNAT4 isomorph of system A amino acid transporter is expressed in human placenta. Am J Physiol Cell Physiol 2006; 290:C305–C312.

12. Cleaj JK, Lewis RM. The mechanisms and regulation of placental amino acid transport to the human foetus. J Neuroendocrinol 2008; 20:419–426.

13. Jansson T, Ekstrand Y, Bjorn C, Wennergren M, Powell TL. Alterations in the activity of placental amino acid transporters in pregnancies complicated by diabetes. Diabetes 2002; 51:2214–2219.

14. Verrey F, Closs EI, Wagner CA, Palacin M, Endou H, Kanai Y. CATs and HATs: the SLC7 family of amino acid transporters. Pflugers Arch 2004; 447:532–542.

15. Hoeftli SD, Smith CH. Alanine transport-systems in isolated basal plasma-membrane of human-placenta. Am J Physiol 1989; 256: C630–C637.

16. Kudo Y, Boyd CAR. Characterization of amino-acid-transport systems in human placental basal membrane-vesicles. Biochim Biophys Acta 1990; 1021:169–174.

17. Cleaj JK, Glazier JD, Nuni G, Crozier SR, Day PE, Harvey NC, Robinson SM, Cooper C, Godfrey KM, Hanson MA, Lewis RM. Facilitated transporters mediate net efflux of amino acids to the fetus across the basal membrane of the placental syncytiotrophoblast. J Physiol 2011; 589:17–997.

18. Mahendran D, Donnai P, Glazier JD, D’Souza SW, Boyd RD, Sibley CP. Amino acid (system A) transporter activity in microvillus membrane vesicles from the placenta of appropriate and small for gestational age babies. Pediatr Res 1993; 34:661–665.

19. Glazier JD, Cetin I, Perugino G, Ronzoni S, Grey AM, Mahendran D, Marconi AM, Pardi G, Sibley CP. Association between the activity of the system A amino acid transporters in the microvillus plasma membrane of the human placenta and severity of fetal compromise in intrauterine growth restriction. Pediatr Res 1997; 42:514–519.

20. Cetin I, Marconi AM, Bozetti P, Sereni LP, Corbetta C, Pardi G, Battaglia FC. Umbilical amino-acid concentrations in appropriate and small for gestational-age infants–biochemical difference present in utero. Am J Obstet Gynecol 1988; 158:120–126.

21. Pantham P, Rosario FJ, Nijland M, Cheung A, Nathanielsz PW, Powell TL, Galan HL, Li C, Jansson T. Reduced placental amino acid transport in response to maternal nutrient restriction in the baboon. Am J Physiol Regul Integr Comp Physiol 2015; 309:R740–R746.

22. Schlabritz-Louitsevitch NE, Hubbard GB, Kia J, Pardi C, Giles M. Maternal and fetal baboon serum amino acid concentrations. Br J Nutr 2001; 87:R287–R294.

23. Schlabritz-Louitsevitch NE, Ballesteros B, Dudley C, Jenkins S, Hubbard G, Burton CJ, Nathanielsz PW. Moderate maternal nutrient restriction, but not glucocorticoid administration, leads to placental morphological changes in the baboon (Papio sp.). Placenta 2007; 28:783–793.

24. Illsey NP, Wang ZQ, Gray A, Sellers MC, Jacobs MM. Simultaneous preparation of paired, microvillus and basal membranes from human placenta. Biochim Biophys Acta 1990; 1029:218–226.

25. Johansson M, Jansson T, Powell TL. NA-K+/-ATPase is distributed to microvillus and basal membrane of the syncytiotrophoblast in human placenta. Am J Physiol-Regul Integr Comp Physiol 2000; 279:R287–R294.

26. Bastin J, Drakesmith H, Rees M, Sargent I, Townsend A. Localisation of proteins of iron metabolism in the human placenta and liver. Br J Haematol 2006; 134:532–543.

27. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248–254.

28. Ling R, Bridges CC, Sugawara M, Fujita T, Leibach FH, Prasad PD, Ganapathy V. Involvement of transporter recruitment as well as gene expression in the substrate-induced adaptive regulation of amino acid transport system A. Biochim Biophys Acta Biocmembr 2001; 1512:15–21.

29. Park SY, Kim JK, Kim JJ, Choi BK, Jung KY, Lee S, Park KJ, Chairoinouga A, Kanai Y, Endou H, Kim DK. Reabsorption of neutral amino acids mediated by amino acid transporter LAT2 and TAT1 in the basolateral membrane of proximal tubule. Arch Pharmacol Res 2005; 28:421–432.

30. Carter AM. Animal models of human placentaation—a review. Placenta 2007; 28(Suppl A):S41–S47.

31. Schlabritz-Louitsevitch NE, Hubbard GB, Jenkins SL, Martin HC, Snider CS, Frost PA, Leland MM, Havill LM, McDonald TJ, Nathanielsz PW. Ontogeny of hematological cell and biochemical profiles in maternal and fetal baboons (Papio species). J Med Primatol 2005; 34:193–200.

32. McDonald TJ, Wu G, Nijland MJ, Jenkins SL, Nathanielsz PW, Jansson T. Effect of 30% nutrient restriction in the first half of gestation on fetal and maternal baboon serum amino acid concentrations. Br J Nutr 2013; 109:1382–1388.

33. Marconi AM, Paolini CL, Stramare L, Cetin I, Fennessey PV, Pardi G, Battaglia FC. Steady state maternal-fetal leucine enrichments in normal and intrauterine growth-restricted pregnancies. Pediatr Res 1999; 46:114–119.

34. Paolini CL, Marconi AM, Ronzoni S, Di Noio M, Fennessey PV, Pardi G, Battaglia FC. Placental transport of leucine, phenylalanine, glycine, and proline in intrauterine growth-restricted pregnancies. J Clin Endocrinol Metab 2001; 86:5427–5432.

35. Teodoro GFR, Vianna D, Torres-Leal FL, Pantaleao LC, Matos-Neto EM, Donato J, Tirapegui J. Leucine is essential for attenuating fetal growth restriction in the baboon (Papio sp.). Am J Obstet Gynecol 1988; 158:120–126.

36. Jansson T, Illsley NP. Osmotic water permeabilities of human placental microvillus and basal membranes. J Membr Biol 1988; 109:1382–1388.

37. Burton GJ, Nathanielsz PW. Moderate maternal nutrient restriction, but not glucocorticoid administration, leads to placental morphological changes in the baboon (Papio sp.). Placenta 2007; 28:783–793.
PV, Battaglia FC. In-vivo placental transport of glycine and leucine in human pregnancies. Pediatr Res 1995; 37:571–575.

39. Casanello P, Sobrevia L. Intrauterine growth retardation is associated with reduced activity and expression of the cationic amino acid transport systems $y^{+}$hCAT-1 and $y^{+}$hCAT-2B and lower activity of nitric oxide synthase in human umbilical vein endothelial cells. Circ Res 2002; 91:127–134.

40. Vadgama JV, Evered DF. Characteristics of L-citrulline transport across rat small intestine in vitro. Pediatr Res 1992; 32:472–478.

41. Mitsuoka K, Shirasaka Y, Fukushima A, Sato M, Nakamura T, Nakaniishi T, Tamai I. Transport characteristics of L-citrulline in renal apical membrane of proximal tubular cells. Biopharm Drug Dispos 2009; 30:126–137.

42. Cetin I, Corbetta C, Sereni LP, Marconi AM, Bozzetti P, Pardi G, Battaglia FC. Umbilical amino-acid-concentrations in normal and growth-retarded fetuses sampled in utero by cordocentesis. Am J Obstet Gynecol 1990; 162:253–261.

43. Constancia M, Angiolini E, Sandovici I, Smith P, Smith R, Kelsey G, Dean W, Ferguson-Smith A, Sibley CP, Reik W, Fowden A. Adaptation of nutrient supply to fetal demand in the mouse involves interaction between the Igf2 gene and placental transporter systems. Proc Natl Acad Sci U S A 2005; 102:19219–19224.

44. Angiolini E, Coan PM, Sandovici I, Iwajomo OH, Peck G, Burton GI, Sibley CP, Reik W, Fowden AL, Constancia M. Developmental adaptations to increased fetal nutrient demand in mouse genetic models of Igf2-mediated overgrowth. FASEB J 2011; 25:1737–1745.

45. Sibley CP, Brownbill P, Dilworth M, Glazier JD. Adaptation in placental nutrient supply to meet fetal growth demand: implications for programming. Placenta 2010; 31:S70–S74.

46. Jansson T, Powell TL. Role of the placenta in fetal programming: underlying mechanisms and potential interventional approaches. Clin Sci (Lond) 2007; 113:1–13.